NCT04958720 (AGAMENON) is a clinical trial of Surgery in Esophageal Cancer, sponsored by Fundación Sociedad Española de Oncologia Médica.

Who is sponsoring NCT04958720?

NCT04958720 is sponsored by Fundación Sociedad Española de Oncologia Médica.

What drugs are being tested in NCT04958720?

Interventions in NCT04958720: Surgery, Chemotherapy, anti-targeted agents and immunotherapy, Radiotherapy.

What condition does NCT04958720 study?

NCT04958720 studies Esophageal Cancer, Gastric Cancer.

Is NCT04958720 still recruiting?

NCT04958720 is currently recruiting now. Last updated 3 July 2025.

Last reviewed 2025-07-03 · How we verify

NCT04958720: AGAMENON

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spanish Registry of Esophagogastric Cancer

Recruiting now Last updated 3 July 2025

What this trial tests

trial testing Surgery in Esophageal Cancer in 10,000 participants. Currently enrolling.

Timeline

27 April 2020

Primary endpoint
1 December 2034

1 December 2035

Quick facts

Lead sponsor	Fundación Sociedad Española de Oncologia Médica
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	10,000
Start date	27 April 2020
Primary completion	1 December 2034
Estimated completion	1 December 2035
Sites	38 locations across Spain

Drugs / interventions tested

Surgery
Chemotherapy, anti-targeted agents and immunotherapy — full drug profile →
Radiotherapy — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Fundación Sociedad Española de Oncologia Médica — full company profile →

Who can join

Adults 18 to 100, any sex, with Esophageal Cancer or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, et al · · 2023 · cited 2× · PMID 36895850 · DOI 10.1177/17588359231157641
Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis.
Mateos L, Jiménez-Fonseca P, Gallego J, Lecumberri A, et al · · 2026 · PMID 41298815 · DOI 10.1038/s41416-025-03264-2

Verify or expand the search:

Other trials of Surgery

Trials testing the same drug.

NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
NCT07352007 — Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular · Phase 2 · not yet recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04958720 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Sociedad Española de Oncologia Médica
Last refreshed: 3 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04958720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing